N+1 Singer reiterated their hold rating on shares of Oxford BioMedica plc (LON:OXB) in a research report sent to investors on Tuesday morning. N+1 Singer currently has a GBX 3.30 ($0.04) price target on the biopharmaceutical company’s stock.

Separately, Jefferies Group assumed coverage on Oxford BioMedica plc in a research report on Friday, October 21st. They issued a buy rating and a GBX 8 ($0.10) target price for the company.

Oxford BioMedica plc (LON:OXB) opened at 3.515 on Tuesday. Oxford BioMedica plc has a 52 week low of GBX 2.98 and a 52 week high of GBX 8.45. The stock’s market capitalization is GBX 93.67 million. The firm has a 50 day moving average price of GBX 3.46 and a 200 day moving average price of GBX 4.15.

COPYRIGHT VIOLATION WARNING: “Oxford BioMedica plc (OXB) Given “Hold” Rating at N+1 Singer” was originally published by Financial Market News and is owned by of Financial Market News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at http://www.financial-market-news.com/oxford-biomedica-plc-oxb-given-hold-rating-at-n1-singer/1210231/.

In other Oxford BioMedica plc news, insider Lorenzo Tallarigo purchased 79,988 shares of Oxford BioMedica plc stock in a transaction that occurred on Monday, September 26th. The stock was purchased at an average price of GBX 3 ($0.04) per share, with a total value of £2,399.64 ($2,976.85).

About Oxford BioMedica plc

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.